Slovak legally-facilitated performance-based Managed Entry Agreements
This method refers to performance-based Managed Entry Agreements (PB-MEAs) introduced in Slovakia through a legal amendment to Act No. 363/2011. These agreements aim to improve patient access to innovative medicines by linking reimbursement to real-world treatment performance. Stakeholders view this as a promising step, though concerns remain about data systems and implementation clarity.
At a glance
Use when
Introducing high-cost innovative medicines with uncertain long-term effectiveness or budget impact; when real-world evidence can inform reimbursement decisions
Avoid when
Data systems are inadequate; when performance metrics cannot be clearly defined or measured; in situations lacking stakeholder agreement
Inputs
Legislative framework (Act No. 363/2011), stakeholder agreements, real-world clinical and economic data, drug pricing and reimbursement proposals
Outputs
Conditional reimbursement decisions, performance monitoring reports, updated pricing or access terms based on outcomes
How it works
Performance-based Managed Entry Agreements (PB-MEAs) in Slovakia are legally facilitated through amendments to Act No. 363/2011 on drug reimbursement. The framework enables conditional reimbursement of medicinal products based on their real-world clinical or economic performance. Data collection, monitoring, and IT infrastructure are critical for implementation. Qualitative stakeholder interviews identified key themes including legislative ambiguity, improved medicine availability, and risks related to data infrastructure and reimbursement design.
- HTA domains
- Clinical Effectiveness, Costs & Economic Evaluation, Organisational aspects
- Categories
- Context & ImplementationPricing/PayerRWE
- Assumptions
- Reliable data collection and IT systems are available; stakeholders can agree on performance metrics; outcomes can be measured and verified in routine practice
- Strengths
- Improves access to innovative treatments,Aligns payment with actual treatment performance,Supports value-based pricing through legal framework
- Limitations
- Ambiguity in legal provisions,Insufficient data infrastructure,Challenges in defining and measuring performance outcomes,Risk of complex and unfavourable reimbursement schemes
- Also known as
- PB-MEA in Slovakia, Slovak performance-based MEA, Legally-facilitated MEA (Slovakia)
Questions this answers
- › How does Slovakia regulate performance-based reimbursement of medicines?
- › What are the perceived benefits of performance-based MEAs in Slovakia?
- › What challenges exist in implementing PB-MEAs in Slovakia?
- › How do stakeholders view the new legal framework for MEAs?
- › What role does data infrastructure play in PB-MEA implementation?
- › What are the risks associated with new reimbursement schemes under the amended law?
References & sources
Similar by meaning
Beta record. Based on the original catalogue summary; primary-source enrichment pending.